stoxline Quote Chart Rank Option Currency Glossary
  
Oculis Holding AG (OCS)
19.23  -0.18 (-0.93%)    11-07 16:00
Open: 19.41
High: 19.41
Volume: 19,065
  
Pre. Close: 19.41
Low: 19.02
Market Cap: 1,006(M)
Technical analysis
2025-11-07 4:46:42 PM
Short term     
Mid term     
Targets 6-month :  23.84 1-year :  25.69
Resists First :  20.41 Second :  22
Pivot price 20.5
Supports First :  17.86 Second :  14.85
MAs MA(5) :  19.34 MA(20) :  20.74
MA(100) :  18.57 MA(250) :  18.58
MACD MACD :  0 Signal :  0.3
%K %D K(14,3) :  10.7 D(3) :  11.3
RSI RSI(14): 42.4
52-week High :  23.07 Low :  14
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ OCS ] has closed above bottom band by 19.1%. Bollinger Bands are 93.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 19.43 - 19.54 19.54 - 19.62
Low: 18.78 - 18.89 18.89 - 18.99
Close: 19.04 - 19.24 19.24 - 19.4
Company Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

Headline News

Fri, 07 Nov 2025
Oculis Holding AG expected to post a loss of 42 rappen a share - Earnings Preview - TradingView

Wed, 05 Nov 2025
Oculis Holding AG (OCS) Q3 2025 Earnings Report Preview: What To Look For - Yahoo Finance

Wed, 05 Nov 2025
Oculis Holding AG Announces Participation in Upcoming Investor Conferences to Showcase Late-Stage Pipeline Developments - Quiver Quantitative

Wed, 05 Nov 2025
Oculis Holding AG Announces Participation in November Investor Conferences to Showcase Clinical Advancements and Pipeline Updates - Quiver Quantitative

Wed, 05 Nov 2025
Oculis (NASDAQ: OCS) to share pipeline updates; 6 pivotal readouts at November events - Stock Titan

Wed, 05 Nov 2025
Oculis to Participate in Upcoming November Investor Conferences - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 52 (M)
Held by Insiders 4.133e+007 (%)
Held by Institutions 6.3 (%)
Shares Short 11 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -7.565e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -7 %
Return on Assets (ttm) 957 %
Return on Equity (ttm) -29.8 %
Qtrly Rev. Growth 764000 %
Gross Profit (p.s.) 50
Sales Per Share -645.85
EBITDA (p.s.) -4.12923e+008
Qtrly Earnings Growth -3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -56 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.03
Price to Cash Flow 0.91
Stock Dividends
Dividend 0
Forward Dividend 65040
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android